Eylea (aflibercept) 8 mg approved in China for wet age-related macular degeneration – Bayer
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of neovascular (wet) age-related macular degeneration (nAMD) in China. The approval is based on positive results from the Phase III PULSAR trial at week 48, which demonstrated comparable efficacy and safety of Eylea 8 mg with treatment intervals of 3 or 4 months (12 or 16 weeks) compared to standard of care Eylea 2 mg (aflibercept 2 mg) with a fixed bi-monthly (every 8 weeks) interval.
In the PULSAR clinical trial Eylea 8 mg met its primary endpoint of non-inferior best corrected visual acuity (BCVA) changes with 3- or 4-monthly dosing regimens compared to Eylea 2 mg (aflibercept 2 mg) with a fixed bi-monthly treatment interval at week 48, following initial monthly doses. The safety profile of Eylea 8 mg was consistent with the well-established safety profile of Eylea 2 mg.
Eylea 8 mg has been approved to date in more than 50 markets for the treatment of nAMD and DME. Further regulatory applications for Eylea 8 mg in additional markets are ongoing.
Eylea 8 mg is the only anti-vascular endothelial growth factor-treatment (anti-VEGF) that is approved for extended treatment intervals of up to 5 months for both, neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME), in the EU and UK. In February 2025, Bayer submitted an application to EMA to expand treatment intervals to up to 6 months with Eylea 8 mg for the treatment of nAMD and DME based on clinical evidence from the PULSAR and PHOTON studies.
“The approval of Eylea 8 mg in China marks a significant advancement in addressing the need for more durable treatment options for patients, caregivers and ophthalmologists,” said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization, and Member of the Pharmaceuticals Leadership Team at Bayer. “Building on the high therapeutic standard of Eylea 2 mg, patients with wet age-related macular degeneration now have the option to benefit from Eylea 8 mg with long treatment intervals and still experience lasting vision gains, rapid and resilient fluid control, and comparable safety to Eylea 2 mg.”
PULSAR is a double-masked, active-controlled pivotal Phase III trial, conducted in multiple centers globally. PULSAR evaluated the efficacy and safety of aflibercept 8 mg in nAMD with 12- and 16-week dosing regimens versus Eylea (aflibercept 2 mg) dosed every 8 weeks, following initial monthly doses, with the primary endpoint of non-inferiority in terms of best corrected visual acuity (BCVA) at week 48. Patients were randomized at baseline and assigned to the three different arms. In PULSAR, 1,009 patients were treated. All patients in the aflibercept 8 mg arms were continuously evaluated under stringent, clinically relevant, patient focused dose regimen modification (DRM) criteria starting from week 16 throughout the study. Patients on aflibercept 8 mg arms were assessed at multiple time points for DRM criteria and may have had their dosing interval shortened to 8 or 12 weeks to secure appropriate disease control through week 48.
